LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors - PubMed (original) (raw)
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
V J Watts et al. Psychopharmacology (Berl). 1995 Apr.
Abstract
The hallucinogenic effects of lysergic acid diethylamide (LSD) have been attributed primarily to actions at serotonin receptors. A number of studies conducted in the 1970s indicated that LSD also has activity at dopamine (DA) receptors. These latter studies are difficult to interpret, however, because they were completed before the recognition of two pharmacologically distinct DA receptor subtypes, D1 and D2. The availability of subtype-selective ligands (e.g., the D1 antagonist SCH23390) and clonal cell lines expressing a homogeneous receptor population now permits an assessment of the contributions of DA receptor subtypes to the DA-mediated effects of LSD. The present study investigated the binding and functional properties of LSD and several lysergamide and analogs at dopamine D1 and D2 receptors. Several of these compounds have been reported previously to bind with high affinity to serotonin 5HT2 (i.e., 3H-ketanserin) sites in the rat frontal cortex (K0.5 5-30 nM). All tested compounds also competed for both D1-like (3H-SCH 23390) and D2-like (3H-spiperone plus unlabeled ketanserin) DA receptors in rat striatum, with profiles indicative of agonists (nH < 1.0). The affinity of LSD and analogs for D2 like receptors was similar to their affinity for 5HT2 sites. The affinity for D1 like receptors was slightly lower (2- to 3-fold), although LSD and several analogs bound to D1 receptors with affinity similar to the prototypical D1 partial agonist SKF38393 (K0.5 ca. 25 nM). A second series of experiments tested the binding and functional properties of LSD and selected analogs in C-6 glioma cells expressing the rhesus macaque D1A receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Watts VJ, et al. Eur J Pharmacol. 1993 Sep 28;242(2):165-72. doi: 10.1016/0014-2999(93)90076-t. Eur J Pharmacol. 1993. PMID: 7902811 - Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Borroto-Escuela DO, et al. Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84. doi: 10.1016/j.bbrc.2013.11.104. Epub 2013 Dec 2. Biochem Biophys Res Commun. 2014. PMID: 24309097 - d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
De Gregorio D, Comai S, Posa L, Gobbi G. De Gregorio D, et al. Int J Mol Sci. 2016 Nov 23;17(11):1953. doi: 10.3390/ijms17111953. Int J Mol Sci. 2016. PMID: 27886063 Free PMC article. Review.
Cited by
- D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors.
Bay-Richter C, O'Callaghan MJ, Mathur N, O'Tuathaigh CM, Heery DM, Fone KC, Waddington JL, Moran PM. Bay-Richter C, et al. Neuropsychopharmacology. 2013 Jul;38(8):1512-20. doi: 10.1038/npp.2013.50. Epub 2013 Feb 19. Neuropsychopharmacology. 2013. PMID: 23422792 Free PMC article. - Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
Brandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Whitelock K, Stratford A, Auwärter V, Halberstadt AL. Brandt SD, et al. Drug Test Anal. 2022 Aug;14(8):1503-1518. doi: 10.1002/dta.3281. Epub 2022 May 29. Drug Test Anal. 2022. PMID: 35524430 Free PMC article. - Psilocybin-induced stimulus control in the rat.
Winter JC, Rice KC, Amorosi DJ, Rabin RA. Winter JC, et al. Pharmacol Biochem Behav. 2007 Oct;87(4):472-80. doi: 10.1016/j.pbb.2007.06.003. Epub 2007 Jun 22. Pharmacol Biochem Behav. 2007. PMID: 17688928 Free PMC article. - Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL. Brandt SD, et al. Drug Test Anal. 2017 Jan;9(1):38-50. doi: 10.1002/dta.1985. Epub 2016 Jun 6. Drug Test Anal. 2017. PMID: 27265891 Free PMC article. - Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL. Brandt SD, et al. Drug Test Anal. 2016 Sep;8(9):891-902. doi: 10.1002/dta.1884. Epub 2015 Oct 12. Drug Test Anal. 2016. PMID: 26456305 Free PMC article.
References
- Mol Pharmacol. 1992 Apr;41(4):652-9 - PubMed
- Psychopharmacology (Berl). 1978 Oct 31;59(2):113-6 - PubMed
- J Neural Transm Suppl. 1992;36:163-77 - PubMed
- Eur J Pharmacol. 1991 Aug 14;207(4):277-86 - PubMed
- Experientia. 1968 Jul 15;24(7):743-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous